Global Ocular Drug Delivery Market Size study & Forecast, by Technology (Topical, Iontophoresis, Ocular Insert, Intraocular Implants, In Situ Gel Punctal Plugs, Others), by Formulation Type (Liposomes Nanoparticles, Solution, Emulsion, Suspension, Ointmen

Global Ocular Drug Delivery Market Size study & Forecast, by Technology (Topical, Iontophoresis, Ocular Insert, Intraocular Implants, In Situ Gel Punctal Plugs, Others), by Formulation Type (Liposomes Nanoparticles, Solution, Emulsion, Suspension, Ointment), by Disease Type (Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Macular Degeneration, Cataract, Others) and by End User (Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers, Homecare Settings) and Regional Analysis, 2023-2030

Global Ocular Drug Delivery Market is valued approximately USD xxx billion in 2022 and is anticipated to grow with a healthy growth rate of more than xxx over the forecast period 2023-2030. Ocular Drug Delivery refers to a dosage form, vehicle, or system used to give or transport medication to the eye for the treatment of any condition that involves or affects vision. The eye is a very important organ that is susceptible to several illnesses. In addition to having an impact on the body, many eye conditions can cause blindness. It varies from straightforward implants for intraocular tissue to basic sterile eye drops for the ocular surface. The major factors driving the growth of the global ocular drug delivery technology market are low bioavailability of drugs in conventional ocular therapies, an increase in the incidence of glaucoma and macular degeneration, growing demand for targeted ocular drug delivery techniques, and an increase in the number of approvals from government regulations for new ocular drug delivery techniques. Favourable reimbursement policies and increased investment for the development of innovative drug delivery systems can assist drive market expansion.

Growing need for tailored ocular medicine delivery systems due to rise in glaucoma and macular degeneration rates. According to the World Health Organization in 2020, after cataract (35.2%) and uncorrected refractive error (20.3%), glaucoma is the third greatest cause of blindness (8.5%). According to estimate, 2.9 million individuals are blind from glaucoma, and 4 million people have some form of visual impairment. In the worldwide pool of vision loss, it was projected that the numbers would rise to 4.5 million for visual impairment and 3.2 million for blindness by 2020, respectively. Another recent systematic analysis reveals that glaucoma affects roughly 64 million individuals globally between the ages of 40 and 80, with that number anticipated to rise to 76 million by the year 2020. Additionally, the use of ocular penetration enhancers such as para-cellular pathways and phase transitions systems and the protective barrier systems of the human eye impede medication delivery effectiveness is projected to expand the market for ocular drug delivery systems. However, the high cost of production and drug related side effects stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Ocular Drug Delivery Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to availability of highly developed products and skilled professionals, growing governmental emphasis on R&D operations, well-established infrastructure for healthcare and research. Additionally, it is projected that an increase in the frequency of eye problems in this area would promote regional growth. Asia Pacific is expected to grow significantly during the forecast period, owing to the establishment of R&D facilities by prominent manufacturers in emerging nations, increasing prevalence of eye diseases, growing geriatric population, increasing healthcare expenditure, and favorable regulatory environment in the region.

Major market player included in this report are:
Valeant Pharmaceuticals International, Inc.
Taiwan Liposome Company, Ltd.
Ocular Therapeutix, Inc.
Graybug Vision Inc.
EyeGate Pharma
Clearside Biomedical, Inc.
Alimera Sciences
Envisia Therapeutics
Allergan, Plc.
AbbVie Inc.

Recent Developments in the Market:
 In February 2022, Alimera Sciences Europe Limited, its Irish-based European subsidiary, has launched ILUVIEN for non-infectious posterior uveitis in Spain through its distribution partner, Brill Pharma (Brill). Alimera Sciences, Inc. is a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with maintaining better vision longer.
 In October 2021, Allergan, an Abbie company, announced that it will present new pooled analyses and post-hoc results from the Phase 3 trials of AGN-190584 (pilocarpine HCI ophthalmic solution 1.25%), an investigational novel treatment for presbyopia, at Academy 2021, the American Academy of Optometry's annual meeting, which will be held November 3-6. Clinical data for near and intermediate vision, functional near vision, effectiveness for post-LASIK patients, and patient experience were all presented.

Global Ocular Drug Delivery Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Technology, Formulation Type, Disease Type, End User, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Technology:
Topical
Iontophoresis
Ocular Insert
Intraocular Implants
In Situ Gel Punctal Plugs
Others
By Formulation Type
Liposomes Nanoparticles
Solution
Emulsion
Suspension
Ointment
By Disease Type:
Glaucoma
Diabetic Retinopathy
Dry Eye Syndrome
Macular Degeneration
Cataract
Others
By End User:
Hospitals
Ophthalmic Clinics
Ambulatory Surgical Centers
Homecare Settings
By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Valeant Pharmaceuticals International, Inc.
Taiwan Liposome Company, Ltd.
Ocular Therapeutix, Inc.
Graybug Vision Inc.
EyeGate Pharma
Clearside Biomedical, Inc.
Alimera Sciences
Envisia Therapeutics
Allergan, Plc.
AbbVie Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.